Roopa Industries Ltd
Incorporated in 1985, Roopa Industries Ltd is in the business of TPP and its allied products[1]
- Market Cap ₹ 40.1 Cr.
- Current Price ₹ 51.0
- High / Low ₹ 63.4 / 38.1
- Stock P/E 9.51
- Book Value ₹ 22.4
- Dividend Yield 0.00 %
- ROCE 15.0 %
- ROE 23.2 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 48.4 to 62.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 | 31 | 30 | 19 | 30 | 28 | 29 | 51 | 76 | 70 | 121 | 128 | 126 | |
| 29 | 31 | 28 | 22 | 28 | 26 | 26 | 48 | 72 | 66 | 117 | 119 | 117 | |
| Operating Profit | 2 | -1 | 2 | -3 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 8 | 8 |
| OPM % | 7% | -2.8% | 7% | -14% | 8% | 7% | 10% | 7% | 5% | 6% | 3.4% | 6% | 7% |
| -0 | 3 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | -4 | -4 | |
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 0 | 0 |
| Tax % | 11% | 35% | 56% | -22% | 24% | 54% | 24% | 26% | 25% | 30% | 25% | 56% | |
| 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 0 | |
| EPS in Rs | 0.20 | 0.22 | 0.24 | 0.69 | 0.76 | 0.47 | 0.92 | 1.30 | 1.72 | 1.93 | 2.58 | 0.10 | 0.16 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 35% |
| 3 Years: | 19% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 37% |
| 5 Years: | 41% |
| 3 Years: | 44% |
| TTM: | 107% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 29% |
| 3 Years: | 9% |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 13% |
| 3 Years: | 15% |
| Last Year: | 23% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 8 | 10 | 10 |
| 8 | 8 | 11 | 16 | 15 | 14 | 13 | 12 | 19 | 26 | 33 | 31 | |
| 8 | 8 | 8 | 10 | 11 | 14 | 21 | 24 | 24 | 23 | 26 | 23 | |
| Total Liabilities | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 | 72 |
| 8 | 7 | 7 | 6 | 6 | 11 | 10 | 10 | 10 | 9 | 8 | 8 | |
| CWIP | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 | 18 | 22 | 27 | 26 | 28 | 36 | 39 | 46 | 55 | 68 | 64 | |
| Total Assets | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 | 72 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | -1 | -5 | 4 | 2 | -1 | 2 | -0 | 2 | -7 | 5 | |
| -0 | 0 | -0 | 2 | -2 | 1 | 1 | 4 | -1 | 1 | 2 | -0 | |
| -0 | -1 | 2 | 2 | -2 | -3 | -1 | -5 | 2 | -2 | 5 | -8 | |
| Net Cash Flow | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | -3 |
| Free Cash Flow | 0 | 1 | -2 | -7 | 2 | 2 | -1 | 2 | -2 | 2 | -7 | 4 |
| CFO/OP | 28% | -146% | -50% | 168% | 184% | 157% | -11% | 78% | 2% | 60% | -144% | 58% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 99 | 146 | 233 | 134 | 157 | 147 | 112 | 34 | 43 | 39 | 63 |
| Inventory Days | 143 | 70 | 139 | 217 | 171 | 256 | 409 | 140 | 109 | 168 | 121 | 102 |
| Days Payable | 132 | 100 | 122 | 177 | 123 | 219 | 280 | 86 | 42 | 96 | 56 | 41 |
| Cash Conversion Cycle | 77 | 69 | 164 | 273 | 182 | 194 | 277 | 166 | 101 | 116 | 104 | 123 |
| Working Capital Days | 32 | 69 | 114 | 214 | 108 | 104 | 114 | 37 | 1 | 10 | 36 | 32 |
| ROCE % | 10% | 10% | 10% | 6% | 9% | 9% | 8% | 10% | 13% | 12% | 12% | 15% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Foreign Exchange Earnings (FOB value of exports) INR Lakhs |
|
|||||||||
| Foreign Exchange Outgo (CIF value of imports) INR Lakhs |
||||||||||
| Number of permanent employees employees |
||||||||||
| Export revenue as % of total revenue % |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Submission of Newspaper Clippings w.r.t publication of Unaudited Financial Results for the 1st Quarter Ended 30th June 2026
-
Submission Of Unaudited Financial Results
- Roopa Industries approved Q1 FY2026 unaudited results on 14 August 2026; profit was Rs 32.84 lakh.
-
Board Meeting Outcome for Submission Of Unaudited Financial Results And Intimation Of Outcome Of The Board Meeting Held On 14Th August, 2026
- Roopa Industries approved Q1 FY2026 unaudited results; profit rose to Rs 32.84 lakh.
-
Submission Of Report On Re-Lodgement Of Transfer Requests Of Physical Shares Under Special Window
- July 2026 re-lodgement report shows nil requests processed, approved, or rejected under SEBI special window.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Submission of Paper publication issued in terms of SEBI Circular No. SEBI/HO/38/13/11(2)2026- MIRSD-PoD/1/3750/2026 dt 30/01/2026
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1][2][3][4]
RIL manufactures Bulk Drugs, Drug Intermediates, Nutraceuticals, and fine chemicals. It produces Active Pharmaceutical Ingredients such as Fluconazole, Sildenafil Citrate, Losartan Potassium and Triphenyl Phosphine (which goes into production of Cephalosporins, Statins etc.,) and Nutraceuticals such as Glucosamine salts.
Its products are used in chemical and pharmaceutical industry and supplied globally